Novartis AG (NYSE:NVS)

91.20
Delayed Data
As of 4:02pm ET
 -1.17 / -1.27%
Today’s Change
64.76
Today|||52-Week Range
93.65
+18.66%
Year-to-Date
Conatus' Emricasan Lags Primary Goal in Liver Function Study
12:57pm / Zacks.comZAK - Paid Partner Content
Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz
Jun 17 / Zacks.comZAK - Paid Partner Content
The 10 Biggest Biotech Stocks
Jun 25 / MotleyFool.comFOO - Paid Partner Content
Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris
Jun 13 / Zacks.comZAK - Paid Partner Content
3 Drugs Under FDA Review With Blockbuster Potential
Jun 20 / MotleyFool.comFOO - Paid Partner Content
Top Analyst Reports for Visa, Netflix & Accenture
Jun 13 / Zacks.comZAK - Paid Partner Content
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status
Jun 18 / Zacks.comZAK - Paid Partner Content
Ligand Inks Oncology Drug Discovery Deal With PhoreMost
Jun 13 / Zacks.comZAK - Paid Partner Content
Roche's Rozlytrek Gets Approval in Japan for Solid Tumors
Jun 18 / Zacks.comZAK - Paid Partner Content
Long-term Survival Benefit Shown for Metastatic Melanoma Patients Treated with Novart...
Jun 04 / PR NewswirePRN - Paid Partner Content
3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal
Jun 18 / MotleyFool.comFOO - Paid Partner Content
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investi...
Jun 03 / PR NewswirePRN - Paid Partner Content
J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study
Jun 17 / Zacks.comZAK - Paid Partner Content